4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Reporting)

DEF 14C - Tempus AI, Inc. (0001717115) (Filer)

144 - Tempus AI, Inc. (0001717115) (Subject)

PRE 14C - Tempus AI, Inc. (0001717115) (Filer)

S-8 POS - Tempus AI, Inc. (0001717115) (Filer)

S-8 POS - Tempus AI, Inc. (0001717115) (Filer)

S-3ASR - Tempus AI, Inc. (0001717115) (Filer)

10-Q - Tempus AI, Inc. (0001717115) (Filer)

8-K - Tempus AI, Inc. (0001717115) (Filer)

144 - Tempus AI, Inc. (0001717115) (Subject)

8-K - Tempus AI, Inc. (0001717115) (Filer)

BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

William Blair downgraded Tempus AI from Outperform to Mkt Perform

TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously

Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00

Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00

Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously

BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously

Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00

BofA Securities initiated coverage of Tempus AI with a rating of Buy and set a new price target of $41.00

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million, a 158.3% year-over-year increase Issued $750 million of 0.75% conv

MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth.  The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degenerat

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and g

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help the

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Personalis, Inc. (NASDAQ:PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (NASDAQ:TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interi

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible

Tempus AI, Inc. ("Tempus") (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the "Notes") in a private placement (the "Offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the Offering was increased from the previously announced offering size of $400 million. Tempus also granted the initial purchasers of the Notes an over-allotment option to purchase, within a 13-day p

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul of healthcare, including beneficial additions such as generative AI apps demonstrating real value. The next wave of AI's healthcare transformation is already taking shape—led by intelligent agents, next-gen diagnostics, and predictive drug discovery platforms. Behind the scenes, a new class of innovators is making tangible progress, with companies like Avant Technologies, Inc. (OTCQB:AVAI), Tempus Ai, Inc. (NASDAQ:TEM), OmniAb, Inc. (NASDAQ:OABI), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Recursion Pharmaceutic

- A portion of the proceeds expected to be used to repay outstanding Term Loans, including immediately paying off the $275MM 2027 Term Loan, reducing interest expense and enhancing financial flexibility. A portion of the proceeds expected to be used to pay for capped call transactions to reduce potential dilution. Additional proceeds expected to be deployed for general corporate purposes. Tempus AI, Inc. ("Tempus") (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due in 2030 (th

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D - Tempus AI, Inc. (0001717115) (Filed by)

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in